Frontiers in Oncology (Aug 2022)
PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma
- Ke Su,
- Lu Guo,
- Kun He,
- Mingyue Rao,
- Jianwen Zhang,
- Xiaoli Yang,
- Xiaoli Yang,
- Xiaoli Yang,
- Weihong Huang,
- Tao Gu,
- Ke Xu,
- Yanlin Liu,
- Jing Wang,
- Jiali Chen,
- Zhenying Wu,
- Lanxin Hu,
- Hao Zeng,
- Hongyan Li,
- Jian Tong,
- Xueting Li,
- Yue Yang,
- Hanlin Liu,
- Yaoyang Xu,
- Zunyuan Tan,
- Xue Tang,
- Xunjie Feng,
- Siyu Chen,
- Binbin Yang,
- Hongping Jin,
- Lechuan Zhu,
- Bo Li,
- Bo Li,
- Bo Li,
- Yunwei Han,
- Yunwei Han,
- Yunwei Han
Affiliations
- Ke Su
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Lu Guo
- Department of Ophthalmology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Kun He
- Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Mingyue Rao
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Jianwen Zhang
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Xiaoli Yang
- Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Xiaoli Yang
- Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China
- Xiaoli Yang
- Academician (Expert) Workstation of Sichuan Province, Luzhou, China
- Weihong Huang
- Clinical Medical College, Southwest Medical University, Luzhou, China
- Tao Gu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Ke Xu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Yanlin Liu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Jing Wang
- Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Jiali Chen
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Zhenying Wu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Lanxin Hu
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Hao Zeng
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Hongyan Li
- Department of Anesthesiology, Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China
- Jian Tong
- Department of Spinal Surgery, No.1 Orthopedics Hospital of Chengdu, Chengdu, China
- Xueting Li
- 0Department of Oncology, 363 Hospital, Chengdu, China
- Yue Yang
- Clinical Medical College, Southwest Medical University, Luzhou, China
- Hanlin Liu
- Clinical Medical College, Southwest Medical University, Luzhou, China
- Yaoyang Xu
- Clinical Medical College, Southwest Medical University, Luzhou, China
- Zunyuan Tan
- Clinical Medical College, Southwest Medical University, Luzhou, China
- Xue Tang
- Clinical Medical College, Southwest Medical University, Luzhou, China
- Xunjie Feng
- Clinical Medical College, Southwest Medical University, Luzhou, China
- Siyu Chen
- Clinical Medical College, Southwest Medical University, Luzhou, China
- Binbin Yang
- Clinical Medical College, Southwest Medical University, Luzhou, China
- Hongping Jin
- Clinical Medical College, Southwest Medical University, Luzhou, China
- Lechuan Zhu
- Clinical Medical College, Southwest Medical University, Luzhou, China
- Bo Li
- Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Bo Li
- Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China
- Bo Li
- Academician (Expert) Workstation of Sichuan Province, Luzhou, China
- Yunwei Han
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Yunwei Han
- Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China
- Yunwei Han
- Academician (Expert) Workstation of Sichuan Province, Luzhou, China
- DOI
- https://doi.org/10.3389/fonc.2022.873830
- Journal volume & issue
-
Vol. 12
Abstract
AimA programmed death 1 (PD-1) inhibitor coupled with radiotherapy and antiangiogenic therapy is a potential therapeutic strategy for advanced hepatocellular carcinoma (HCC). We aimed to determine if circulating tumor cells (CTCs) positive for programmed death-ligand 1 (PD-L1) could be employed as a predictive biomarker in HCC patients receiving triple therapy.MethodsIn this study, HCC patients received a PD-1 inhibitor in combination with intensity-modulated radiotherapy (IMRT) and antiangiogenic therapy. Following IMRT, the PD-1 inhibitor was administrated once every 3 weeks, while the antiangiogenic drug was given once a day. Treatment was continued until the disease progressed. Two mL of peripheral blood was collected at baseline, 1 month, and 3 months after treatment for CTC enrichment using the CytoSorter® system with a CytoSorter™ CTC PD-L1 Kit (Watson Biotech., China).ResultA total of 47 HCC patients receiving the triple therapy were enrolled in this study. Patients with < 2 PD-L1+ CTCs at baseline had a higher objective response rate (ORR) and longer overall survival (OS) than those with ≥ 2 PD-L1+ CTCs (56.5% vs. 16.7%, p = 0.007; not reach vs. 10.8 months, p = 0.001, respectively). The count of PD-L1+ CTCs was found to be an independent predictive biomarker of OS. Furthermore, the objective response was more likely to be achieved in patients with a dynamic decrease in PD-L1+ CTC counts at 1 month after treatment.ConclusionsOur study demonstrated that PD-L1+ CTCs could be a predictive biomarker for HCC patients receiving PD-1 inhibitors in combination with IMRT and antiangiogenic therapy.
Keywords
- programmed death-ligand 1
- circulating tumor cells
- hepatocellular carcinoma
- programmed death 1 inhibitor
- radiotherapy
- antiangiogenic therapy
